These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 23831338)

  • 1. Emerging treatments for pemphigoid diseases.
    Ludwig RJ; Kalies K; Köhl J; Zillikens D; Schmidt E
    Trends Mol Med; 2013 Aug; 19(8):501-12. PubMed ID: 23831338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repetitive immunization breaks tolerance to type XVII collagen and leads to bullous pemphigoid in mice.
    Hirose M; Recke A; Beckmann T; Shimizu A; Ishiko A; Bieber K; Westermann J; Zillikens D; Schmidt E; Ludwig RJ
    J Immunol; 2011 Aug; 187(3):1176-83. PubMed ID: 21705619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential role of interleukin-17 in the pathogenesis of bullous pemphigoid.
    Toosi S; Bystryn JC
    Med Hypotheses; 2010 Apr; 74(4):727-8. PubMed ID: 19945799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bullous pemphigoid and related subepidermal autoimmune blistering diseases.
    Olasz EB; Yancey KB
    Curr Dir Autoimmun; 2008; 10():141-66. PubMed ID: 18460884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enzyme-linked immunosorbent assay in autoimmune blistering diseases: preliminary experience of the Dermatology Department of Cagliari.
    Atzori L; Deidda S; Aste N
    G Ital Dermatol Venereol; 2008 Feb; 143(1):1-8. PubMed ID: 18833046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological therapy of autoimmune blistering diseases.
    Alaibac M
    Expert Opin Biol Ther; 2019 Feb; 19(2):149-156. PubMed ID: 30558452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging treatments for bullous pemphigoid.
    Garrido PM; QueiróS CS; Travassos AR; Borges-Costa J; Filipe P
    J Dermatolog Treat; 2022 Mar; 33(2):649-661. PubMed ID: 32536232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bullous pemphigoid.
    Korman NJ
    Dermatol Clin; 1993 Jul; 11(3):483-98. PubMed ID: 8365034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current Clinical Trials in Pemphigus and Pemphigoid.
    Izumi K; Bieber K; Ludwig RJ
    Front Immunol; 2019; 10():978. PubMed ID: 31130959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogenesis of epidermolysis bullosa acquisita, an autoimmune subepidermal bullous disease.
    Hashimoto T; Ishii N; Ohata C; Furumura M
    J Pathol; 2012 Sep; 228(1):1-7. PubMed ID: 22692770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of IgE in bullous pemphigoid: a review and rationale for IgE directed therapies.
    Messingham KN; Pietras TA; Fairley JA
    G Ital Dermatol Venereol; 2012 Jun; 147(3):251-7. PubMed ID: 22648326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Bullous pemphigoid, primary biliary cirrhosis and vitiligo: a multiple autoimmune syndrome?].
    Marcet B; Sibaud V; Géniaux M; Taieb A
    Ann Med Interne (Paris); 2002 Sep; 153(5):349-50. PubMed ID: 12442082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New methods of therapy for ocular inflammatory autoimmune diseases].
    Kubicka-Trzaska A; Undas A
    Klin Oczna; 2003; 105(6):428-32. PubMed ID: 15049272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current treatments and developments in pemphigoid diseases as paradigm diseases for autoantibody-driven, organ-specific autoimmune diseases.
    Sadik CD; Zillikens D
    Semin Hematol; 2016 Apr; 53 Suppl 1():S51-3. PubMed ID: 27312166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of cost of immune globulin intravenous therapy to conventional immunosuppressive therapy in treating patients with autoimmune mucocutaneous blistering diseases.
    Daoud YJ; Amin KG
    Int Immunopharmacol; 2006 Apr; 6(4):600-6. PubMed ID: 16504922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resolution in bullous pemphigoid.
    Sadik CD; Schmidt E
    Semin Immunopathol; 2019 Nov; 41(6):645-654. PubMed ID: 31732776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of bullous pemphigoid with adjuvant immunoadsorption: a case series.
    Kasperkiewicz M; Schulze F; Meier M; van Beek N; Nitschke M; Zillikens D; Schmidt E
    J Am Acad Dermatol; 2014 Nov; 71(5):1018-20. PubMed ID: 25437968
    [No Abstract]   [Full Text] [Related]  

  • 18. Successful adjuvant treatment of severe bullous pemphigoid by tryptophan immunoadsorption.
    Herrero-González JE; Sitaru C; Klinker E; Bröcker EB; Zillikens D
    Clin Exp Dermatol; 2005 Sep; 30(5):519-22. PubMed ID: 16045683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coexistence of bullous pemphigoid, vitiligo, and thyroid disease: a multiple autoimmune syndrome?
    Tirado-Sánchez A; Montes-de-Oca G
    Dermatol Online J; 2005 Aug; 11(2):20. PubMed ID: 16150228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogenesis of bullous pemphigoid.
    Ujiie H; Nishie W; Shimizu H
    Dermatol Clin; 2011 Jul; 29(3):439-46, ix. PubMed ID: 21605809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.